Applied DNA Sciences special meeting fails due to lack of quorum; warrant approval deferred

BNB PLUS CORP.

Special meeting on Aug 2, 2024 had 4,056,202 shares present, below required majority; adjourned without action.
Proposal sought stockholder approval to exercise Series A and B warrants from May 2024 public offering.
Without approval, company must call a subsequent meeting to seek warrant stockholder approval.
Series Warrants remain unexercisable until Nasdaq-required shareholder approval is obtained.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.